Abstract: PUB142
Mortality Trends of Patients with Systemic Lupus Erythematosus on Dialysis in the Japanese Society for Dialysis Therapy (JSDT) Registry: Web-Based Analysis of Dialysis Data Archives (WADDA) System
Session Information
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Oshiro, Nanako, Dialysis Unit, University of the Ryukyus Hospital, Nishihara-cho, Okinawa, Japan
- Kohagura, Kentaro, Dialysis Unit, University of the Ryukyus Hospital, Nishihara-cho, Okinawa, Japan
- Kusunose, Kenya, Department of Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Nishihara-cho, Okinawa, Japan
- Iseki, Kunitoshi, Nakamura Clinic, Urasoe-city, Japan
Background
There are few reports about the gender-specific prognosis of the dialysis patients with systemic lupus erythematosus (SLE), particularly in recent years since 2015 when treatment with multitarget regimen for lupus nephritis became widely practiced in Japan. We examined the prognosis of SLE on dialysis by gender.
Methods
We used the JSDT annual data of dialysis patients from 2017 to 2022 obtained from the WADDA system. Relative risks (RRs) with 95% confidence intervals (CIs) were obtained from 2017 to 2022 in reference to non-SLE dialysis patients. We examined those with age less than 60 years.
Results
The average of annual number of patients was total 20,087/SLE 437 (female) and total 50,927/SLE 152 (male). The crude mortality rate of all dialysis patients was around 2.5%, and for females, it was around 2.3%, both remaining relatively stable. On the other hand, among patients with SLE, the crude mortality rate of both the overall patient population and females has increased year by year. In female patients with SLE, there was no significant increase in all-cause mortality from 2017 to 2019; 2017 (RR: 1.14, 95% CI: 0.66-1.97, p=0.6188), 2018 (RR: 1.26, 95% CI: 0.73-2.18, p=0.3923), and 2019 (RR:1.51, 95% CI: 0.92-2.47, p=0.0950), respectively. However, continuously since 2020 to 2022: 2020 (RR: 1.76, 95% CI: 1.11-2.80, p=0.0151), 2021(RR 1.91, 95% CI:1.22-3.00, p=0.0042), and 2022 (RR 2.50, 95% CI: 1.69-3.70, p<0.001). In male patients, there was no consistent changes observed: 2017 (RR 0.69, 95% CI: 0.22-2.12, p=0.5183), 2018 (RR 2.21, 95% CI:1.21-4.04, p=0.0091), 2019 (RR 0.73, 95%CI: 0.23-2.24, p=0.5801), 2020 (RR 2.59, 95% CI :1.46-4.60, p=0.0009), 2021 (RR 0.67, 95% CI: 0.21-2.05, p=0.4794). and 2022 (RR 2.15, 95% CI: 1.18-3.93, P=0.0118).
Conclusion
This study revealed an increased risk of all-cause mortality among female dialysis patients with SLE under 60 years old since 2020.